State of Alaska Department of Revenue increased its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 78.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,213 shares of the specialty pharmaceutical company’s stock after buying an additional 4,503 shares during the period. State of Alaska Department of Revenue’s holdings in SciClone Pharmaceuticals were worth $112,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in SCLN. LS Investment Advisors LLC boosted its position in SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 8,355 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,320 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 310 shares during the period. Mason Street Advisors LLC boosted its position in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 881 shares during the period. Finally, OppenheimerFunds Inc. boosted its position in SciClone Pharmaceuticals by 29.9% in the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 3,065 shares during the period. Hedge funds and other institutional investors own 71.84% of the company’s stock.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) traded up 0.45% during trading on Friday, hitting $11.05. The stock had a trading volume of 633,614 shares. The firm has a market cap of $576.71 million, a PE ratio of 13.63 and a beta of 1.71. SciClone Pharmaceuticals, Inc. has a 52 week low of $8.55 and a 52 week high of $11.43. The company’s 50-day moving average is $10.97 and its 200 day moving average is $10.15.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The company had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. Equities analysts expect that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “State of Alaska Department of Revenue Has $112,000 Stake in SciClone Pharmaceuticals, Inc. (SCLN)” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/12/state-of-alaska-department-of-revenue-has-112000-stake-in-sciclone-pharmaceuticals-inc-scln.html.

Separately, Maxim Group set a $14.00 target price on SciClone Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 11th.

In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 40,500 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $10.75, for a total value of $435,375.00. Following the transaction, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Friedhelm Blobel sold 18,536 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $9.44, for a total value of $174,979.84. Following the completion of the transaction, the chief executive officer now directly owns 111,062 shares in the company, valued at $1,048,425.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 235,500 shares of company stock worth $2,479,764. Company insiders own 5.16% of the company’s stock.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.